Study reveals how ‘hypermutated’ malignant brain tumors escape chemotherapy and immunotherapy

An analysis of more than 10,000 gliomas and clinical outcomes reported in Nature by scientists in Boston and Paris found that glioma patients whose tumors were hypermutated actually had no significant benefit when treated with checkpoint blockers.